570,600 Shares in DexCom, Inc. $DXCM Purchased by Employees Retirement System of Texas

Employees Retirement System of Texas acquired a new position in DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 570,600 shares of the medical device company’s stock, valued at approximately $37,871,000.

Other large investors have also modified their holdings of the company. Gradient Investments LLC increased its holdings in shares of DexCom by 13.8% in the 4th quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock worth $22,035,000 after acquiring an additional 40,343 shares during the period. Nordea Investment Management AB increased its stake in DexCom by 118.6% during the 4th quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock valued at $16,988,000 after buying an additional 137,986 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in DexCom by 11.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 212,045 shares of the medical device company’s stock valued at $14,269,000 after buying an additional 21,352 shares during the period. NEOS Investment Management LLC increased its stake in DexCom by 58.7% during the 3rd quarter. NEOS Investment Management LLC now owns 175,982 shares of the medical device company’s stock valued at $11,842,000 after buying an additional 65,066 shares during the period. Finally, Banco Santander S.A. increased its stake in DexCom by 28.9% during the 3rd quarter. Banco Santander S.A. now owns 250,310 shares of the medical device company’s stock valued at $16,843,000 after buying an additional 56,062 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity

In other news, insider Kevin R. Sayer sold 26,759 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the completion of the transaction, the insider owned 382,482 shares in the company, valued at approximately $27,538,704. This trade represents a 6.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total transaction of $107,168.00. Following the transaction, the executive vice president owned 111,204 shares of the company’s stock, valued at approximately $7,010,300.16. This trade represents a 1.51% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 32,871 shares of company stock worth $2,306,638. Corporate insiders own 0.28% of the company’s stock.

DexCom Stock Performance

NASDAQ:DXCM opened at $72.01 on Wednesday. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The company has a 50-day moving average of $63.87 and a 200-day moving average of $66.18. The firm has a market cap of $27.79 billion, a price-to-earnings ratio of 30.77, a price-to-earnings-growth ratio of 1.19 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter last year, the firm posted $0.32 EPS. The business’s revenue for the quarter was up 15.0% on a year-over-year basis. Analysts forecast that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DXCM has been the topic of several research analyst reports. Raymond James Financial set a $81.00 target price on shares of DexCom in a research note on Friday, May 1st. Benchmark initiated coverage on shares of DexCom in a research note on Monday, May 11th. They set a “buy” rating and a $77.00 target price on the stock. Mizuho set a $75.00 target price on shares of DexCom in a research note on Friday, May 1st. Bank of America lowered their target price on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Finally, Citigroup reissued a “buy” rating and set a $79.00 target price (down from $84.00) on shares of DexCom in a research note on Monday, May 4th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $82.21.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.